AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Taysha Gene Therapies Inc (NASDAQ:TSHA)
5.805 USD
+0.255 4.595%Sponsored Reports
Loading...
| Previous Close (in USD) | 5.55 |
|---|---|
| Change | +0.255 4.595% |
| 52 W H/L (in USD) | 3.890/0.500 |
| EBITDA (in USD) | -70.003M |
| PE Ratio | -- |
| Volume | 338492 |
| Diluted Eps TTM | -0.78 |
| Total Assets (in USD) | 266.994M |
|---|---|
| Total Liabilities (in USD) | 192.057M |
| Revenue TTM (in USD) | 15.451M |
| Cash (in USD) | 144.389M |
| Market Cap (in USD) | 607.809 M |
| Revenue Per Share TTM | 0.133 |
| Gross Profit TTM (in USD) | 2.502M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Employees: 52
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. R. A. Session II | Founder, Pres, CEO & Director | 1979 |
| 2. | Mr. Kamran Alam CPA, M.B.A. | Chief Financial Officer | 1978 |
| 3. | Dr. Suyash Prasad FFPM, M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M | Chief Medical Officer and Head of R&D | 1970 |
| 4. | Mr. Frederick Porter Ph.D. | Chief Technical Officer | NA |
| 5. | Mr. Jim Rouse | Chief Information Officer | NA |
| 6. | Ms. Tracy M. Porter | Chief People Officer | NA |
| 7. | Ms. Emily McGinnis M.P.H. | Chief Patient Officer & Head of Gov. Affairs | NA |
| 8. | Ms. Mishima Gerhart | Chief Regulatory Officer & Head of Quality | NA |
| 9. | Mr. Sean McAuliffe | Chief Commercial Officer | NA |
| 10. | Mr. Greg Gara | Sr. VP of Manufacturing | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+2.315 5.512% | 43.09 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+1.785 4.228% | 43.8 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+14.755 3.445% | 434.95 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+6.860 1.108% | 628.07 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Income Before Tax | -166.014M | -174.523M | -60.011M | - |
| Minority Interest | - | - | - | - |
| Net Income | -169.581M | -175.459M | -43M | - |
| Selling General Administrative | 37.36M | 41.324M | 11.109M | - |
| Gross Profit | 2.502M | - | - | - |
| Reconciled Depreciation | 1.172M | 0.492M | 0.009M | - |
| Ebit | -162.447M | -173.267M | -43.002M | -4.46M |
| Ebitda | -125.796M | -173.095M | -59.983M | - |
| Depreciation And Amortization | 36.651M | 0.172M | -16.981M | - |
| Operating Income | -162.447M | -173.267M | -43.002M | - |
| Other Operating Expenses | 128.529M | 173.267M | 43.002M | - |
| Interest Expense | 3.798M | 1.428M | 0.028M | 0M |
| Tax Provision | - | - | - | - |
| Interest Income | 0.249M | 0.172M | 0.049M | - |
| Net Interest Income | -3.549M | -1.256M | 0.021M | - |
| Income Tax Expense | 3.567M | 0.936M | -17.011M | - |
| Total Revenue | 2.502M | 0M | 0M | - |
| Total Operating Expenses | 128.529M | 173.267M | 43.002M | - |
| Cost Of Revenue | - | - | - | - |
| Total Other Income Expense Net | -3.567M | -1.256M | -17.009M | - |
| Net Income From Continuing Ops | -166.014M | -174.523M | -60.011M | - |
| Net Income Applicable To Common Shares | - | -174.523M | -60.011M | -4.46M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 266.994M | 126.276M | 213.956M | 258.881M | 0.015M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 4.798M | 8.537M | 10.499M | 6.626M | 0.015M |
| Total Liab | 192.057M | 125.327M | 118.573M | 7.579M | 0.15M |
| Total Stockholder Equity | 74.937M | 0.949M | 95.383M | 251.302M | -0.135M |
| Other Current Liab | 10.638M | 16.766M | 29.983M | 5.135M | 0.15M |
| Common Stock | 0.002M | 0.001M | - | - | - |
| Capital Stock | 0.002M | 0.001M | 0M | 0M | 0M |
| Retained Earnings | -513.007M | -401.441M | -235.649M | -61.126M | -1.115M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 3.953M | 3.744M | 0.715M | - |
| Cash | 144.389M | 87.88M | 149.103M | 251.253M | - |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 36.756M | 62.79M | 51.746M | 7.129M | 0.15M |
| Current Deferred Revenue | 18.106M | 33.557M | - | - | - |
| Net Debt | -83.282M | -27.952M | -86.011M | -251.253M | - |
| Short Term Debt | 1.646M | 1.521M | - | - | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 61.107M | 59.928M | 63.092M | - | - |
| Other Stockholder Equity | 587.942M | 402.389M | 331.032M | 312.428M | 0.98M |
| Property Plant Equipment | - | - | 50.61M | 0.287M | - |
| Total Current Assets | 149.187M | 96.417M | 159.602M | 251.253M | 0.015M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | - | - | - | - | - |
| Long Term Debt | 40.508M | 37.967M | 37.192M | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 6.366M | 10.946M | 21.763M | 1.994M | - |
| Accumulated Other Comprehensive Income | 0M | - | - | - | - |
| Non Currrent Assets Other | 0.985M | 3.953M | 3.744M | 7.341M | - |
| Non Current Assets Total | 117.807M | 29.859M | 54.354M | 7.628M | 0M |
| Capital Lease Obligations | 20.599M | 21.961M | 25.9M | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Investments | -24.93M | -21.554M | -9.082M | - |
| Total Cashflows From Investing Activities | -24.93M | -21.554M | -9.082M | -9.082M |
| Total Cash From Financing Activities | 52.097M | 39.083M | 291.064M | 291.064M |
| Net Income | -166.014M | -174.523M | -60.011M | -4.46M |
| Change In Cash | -61.223M | -99.513M | 251.253M | 251.253M |
| Begin Period Cash Flow | 151.74M | 251.253M | 0M | - |
| End Period Cash Flow | 90.517M | 151.74M | 251.253M | - |
| Total Cash From Operating Activities | -88.39M | -117.042M | -30.729M | -30.729M |
| Depreciation | 1.172M | 0.492M | 0.009M | 0.009M |
| Other Cashflows From Investing Activities | -0.061M | -0.061M | -9M | -0.061M |
| Dividends Paid | - | - | - | - |
| Change To Inventory | - | - | - | - |
| Sale Purchase Of Stock | - | - | 291.064M | - |
| Other Cashflows From Financing Activities | -1.147M | 39.083M | 126.883M | -0.79M |
| Capital Expenditures | 24.869M | 21.554M | 9.082M | 0.082M |
| Change In Working Capital | 18.518M | 28.667M | -0.111M | - |
| Other Non Cash Items | 39.891M | 10.138M | 26.03M | - |
| Free Cash Flow | -113.259M | -138.596M | -39.811M | - |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Select Biotechnology | 2 years ago | 8767782 |
| 2. | Fidelity Growth Compy Commingled Pl O | 2 years ago | 5443423 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 4026826 |
| 4. | Fidelity Growth Company Fund | 2 years ago | 3613791 |
| 5. | Polar Capital Biotech S Inc | 2 years ago | 2500000 |
| 6. | Eagle Small Cap Core Inst'l | 2 years ago | 1561568 |
| 7. | Fidelity Growth Company K6 | 2 years ago | 1471543 |
| 8. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 1436694 |
| 9. | iShares Biotechnology ETF | 2 years ago | 951948 |
| 10. | Fidelity Series Growth Company | 2 years ago | 936201 |
| 11. | MEDICAL BioHealth EUR Acc | 2 years ago | 793719 |
| 12. | Fidelity Extended Market Index | 2 years ago | 527454 |
| 13. | Carillon Eagle Small Cap Core CIT | 2 years ago | 329143 |
| 14. | Kovitz ValuePlus | 2 years ago | 277778 |
| 15. | Eagle Small Mid Cap Core - Instl | 2 years ago | 226899 |
| 16. | BlackRock Extended Equity Market K | 2 years ago | 215411 |
| 17. | RIM Global Bioscience EUR | 2 years ago | 164000 |
| 18. | Fidelity Total Market Index | 2 years ago | 163554 |
| 19. | Fidelity Series Total Market Index | 2 years ago | 122997 |
| 20. | Fidelity Nasdaq Composite Index | 2 years ago | 109633 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | FMR Inc | 2 years ago | 22439124 |
| 2. | venBio Select Advisor LLC | 2 years ago | 18650000 |
| 3. | RTW INVESTMENTS, LLC | 2 years ago | 18593185 |
| 4. | RA Capital Management, LLC | 2 years ago | 18472503 |
| 5. | Vanguard Group Inc | 2 years ago | 5917414 |
| 6. | Baker Bros Advisors LP | 2 years ago | 4004756 |
| 7. | Eversept Partners, LLC | 2 years ago | 3780714 |
| 8. | Tybourne Capital Management (HK) Ltd | 2 years ago | 3700000 |
| 9. | Longwood Capital Partners LLC | 2 years ago | 3333333 |
| 10. | Millennium Management LLC | 2 years ago | 3135317 |
| 11. | Octagon Capital Advisors LP | 2 years ago | 3030000 |
| 12. | BlackRock Inc | 2 years ago | 2699238 |
| 13. | Polar Capital Holdings PLC | 2 years ago | 2518909 |
| 14. | Eagle Asset Management, Inc. | 2 years ago | 1789394 |
| 15. | Susquehanna International Group, LLP | 2 years ago | 1428146 |
| 16. | T. Rowe Price Associates, Inc. | 2 years ago | 1099329 |
| 17. | Renaissance Technologies Corp | 2 years ago | 1097400 |
| 18. | StemPoint Capital LP | 2 years ago | 1087785 |
| 19. | Artal Group S A | 2 years ago | 3663104 |
| 20. | TCG Crossover Management, LLC | 2 years ago | 2912861 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...